Pricing and reimbursement delays continue to impact biopharma revenue streams
Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to…
17 Feb 2026
Pharma companies venture further afield in search of R&D
With manufacturing onshoring a continuing point of discussion in the industry, many pharma companies went the opposite way for R&D in 2025, deciding to conduct innovation overseas. According to a…
17 Feb 2026
Teijin and Aska Pharmaceutical to co-develop gynaecological drugs
Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases. The collaboration aims to expedite early-stage drug discovery focused on…
17 Feb 2026
ExCellThera secures German NUB Status 1 listing for Zemcelpro
ExCellThera and its wholly owned subsidiary Cordex Biologics have received a Status 1 listing from the Neue Untersuchungs- und Behandlungsmethoden (NUB) programme in Germany for Zemcelpro (dorocubicel), also known as…
16 Feb 2026
Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages
In a bid to avoid previous shortages of injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs), Eli Lilly has already started to assemble a stockpile of its oral weight loss drug orforglipron.…
16 Feb 2026
PTC pulls Translarna NDA after unfavourable FDA feedback
PTC Therapeutics has chosen to withdraw its resubmitted new drug application (NDA) for Duchenne muscular dystrophy (DMD) therapy, Translarna (ataluren), marking another significant setback in the drug’s US development programme.…
16 Feb 2026
FDA issues complete response letter to Disc Medicine’s bitopertin NDA
Disc Medicine has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) concerning its new drug application (NDA) for bitopertin for erythropoietic protoporphyria (EPP). The…